Zingerone attenuates vancomycin-induced hepatotoxicity in rats through regulation of oxidative stress, inflammation and apoptosis. 2020

Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
Department of Biochemistry, Faculty of Veterinary Medicine, Ataturk University, 25240 Erzurum, Turkey. Electronic address: sefa.kucukler@atauni.edu.tr.

OBJECTIVE Vancomycin (VCM) is a glycopeptide antibiotic widely used to treat serious infections caused by methicillin-resistant Staphylococcus aureus and has been associated with some severe side effects such as hepatotoxicity and nephrotoxicity. However, the underlying mechanism of VCM-induced hepatotoxicity is not yet fully understood. Therefore, the current study was designed to evaluate the protective effects of zingerone (Zin) against VCM-induced hepatotoxicity in rats. METHODS VCM was intraperitoneally administered at a dose of 200 mg/kg body weight (b.w.) for 7 days alone and in combination with the orally administered Zin (25 and 50 mg/kg b.w). RESULTS Zin treatment significantly improved VCM-induced hepatic lipid peroxidation, glutathione depletion, reduced antioxidant enzyme (superoxide dismutase, catalase and glutathione peroxidase) activities and liver function markers (aspartate aminotransferase, alkaline phosphatase and alanine aminotransferase). Histopathological integrity and immunohistochemical expression of 8-hydroxy-2'-deoxyguanosine (8-OHdG) in the VCM-induced liver tissue were ameliorated after Zin administration. In addition, Zin reversed the changes in levels and/or activities of inflammatory and apoptotic parameters such as nuclear factor kappa B (NF-κB), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), p53, cysteine aspartate specific protease-3 (caspase-3), cysteine aspartate specific protease-8 (caspase-8), cytochrome c, Bcl-2 associated X protein (Bax) and B-cell lymphoma-2 (Bcl-2) in the VCM-induced hepatotoxicity. CONCLUSIONS Collectively, these results reveal probable ameliorative role of Zin against VCM-induced hepatotoxicity.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D006139 Guaiacol An agent thought to have disinfectant properties and used as an expectorant. (From Martindale, The Extra Pharmacopoeia, 30th ed, p747) 2-Hydroxy-Anisole,2-Hydroxyanisole,2-Methoxy-Phenol,2-Methoxyphenol,Guaicol,Methyl Catechol,Catechol, Methyl
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D014640 Vancomycin Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. AB-Vancomycin,Diatracin,VANCO-cell,Vanco Azupharma,Vanco-saar,Vancocin,Vancocin HCl,Vancocine,Vancomicina Abbott,Vancomicina Chiesi,Vancomicina Combino Phar,Vancomicina Norman,Vancomycin Hexal,Vancomycin Hydrochloride,Vancomycin Lilly,Vancomycin Phosphate (1:2),Vancomycin Phosphate (1:2), Decahydrate,Vancomycin Sulfate,Vancomycin-ratiopharm,Vancomycine Dakota,Hydrochloride, Vancomycin,Sulfate, Vancomycin
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015227 Lipid Peroxidation Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. Lipid Peroxidations,Peroxidation, Lipid,Peroxidations, Lipid
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB

Related Publications

Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
January 2019, Antimicrobial agents and chemotherapy,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
December 2022, International journal of molecular sciences,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
September 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
December 2023, Medicina (Kaunas, Lithuania),
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
August 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
January 2021, Pakistan journal of pharmaceutical sciences,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
May 2022, Saudi journal of biological sciences,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
October 2020, Journal of biochemical and molecular toxicology,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
June 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Sefa Kucukler, and Ekrem Darendelioğlu, and Cuneyt Caglayan, and Adnan Ayna, and Serkan Yıldırım, and Fatih Mehmet Kandemir
June 2017, Acta biochimica et biophysica Sinica,
Copied contents to your clipboard!